StocksMedium•6 November 2026•
1 min read
CAMP4 Therapeutics Reports Narrower-Than-Expected Q3 Loss
Key Facts
1CAMP4 Therapeutics reported a quarterly loss of $0.17 per share, narrower than the Zacks Consensus Estimate of a $0.2 loss.
2The current quarter's results represent an improvement compared to the $0.55 per share loss reported a year ago.
CAMP4 Therapeutics reported a quarterly loss of $0.17 per share for the third quarter of 2026. Zacks reported that this figure was narrower than the $0.2 loss per share anticipated by analyst estimates.
CAMP closed at $3.72 on November 5, 2026, with the stock trading between a low of $3.54 and a high of $3.88 during the session. The current results mark an improvement from the $0.55 per share loss recorded during the same period last year.